Appealing an NCPDP 75 Prior-Authorization Reject: What Actually Works in 2026

You're in the middle of a busy day, a patient is waiting at the pharmacy counter, and the claim just came back with a reject 75. For anyone who's worked in pharmacy billing or prior authorization long enough, that two-digit code carries a familiar sting. Reject 75 — "Prior Authorization Required" — is one of the most common NCPDP transaction rejects out there, and yet it still trips up practices and pharmacies that haven't built a clean process around it. The first thing to know: a reject 75 is not yet a denial to appeal. It tells the pharmacy that the plan wants a prior authorization on file before it will pay the claim. The usual fix is getting the right PA request to the plan, and a formal appeal comes into play only if the plan denies that request. Here's how to work them in 2026.

What Reject 75 Actually Means (And Why It Happens More Than It Should)

Let's start with the basics, because the details matter here. When a pharmacy submits a claim through the NCPDP standard transaction set and gets back reject 75, the PBM is saying that the drug requires prior authorization — and either no PA is on file, or the one that exists doesn't match the claim being submitted.

That sounds simple, but the reasons behind a 75 reject are surprisingly varied:

• No PA was ever submitted — the prescriber or their staff didn't know it was required
• PA was approved but linked to the wrong NPI, drug strength, or quantity
• The approved PA has lapsed — this is increasingly common with maintenance medications on annual review cycles
• The drug was added to the formulary's PA-required tier after the PA was first approved
• Step therapy requirements weren't documented correctly in the original submission

A common mistake: pharmacies and practices assume that because a PA was approved last year, it'll carry forward automatically. Don't count on it. Many approvals carry an end date, and formularies change, including at the start of each plan year. If you haven't audited your active PAs in the last six months, now is a good time.

Before You Appeal: Do This First

Here's where a lot of teams waste time: they jump straight into an appeal without doing the diagnostic work. The order matters. If no valid PA is on file, the prescriber submits a PA request. For a Medicare Part D plan, that request is a coverage determination, or an exception request if the drug is off formulary or the patient needs a tiering exception, and the enrollee, the prescriber or the enrollee's representative can file it (CMS). The appeal comes only after the plan says no: a redetermination for Part D, an internal appeal for a commercial plan. If a PA is on file but the claim still rejects, the fix is usually to get the PA corrected or a new one issued for the drug, strength and prescriber on the claim, not an appeal. Take fifteen minutes to find out which situation you are in before you draft anything.

Verify what the PBM actually has on file. Call the PBM's provider line (not the member line — you'll get better information faster) and confirm whether a PA exists, when it was approved, what drug it covers, and whether it's still active. Ask them to read back the covered NDC or drug name exactly. You'd be surprised how often the approved PA is for a 10mg tablet and the claim is submitting for a 20mg tablet.

Pull the original clinical justification. Whatever was submitted when the PA was first approved — pull that documentation now. You'll need it for the appeal, and it also tells you whether there's a gap you need to fill.

Check the prescriber information. If the prescribing provider changed, even slightly (new group affiliation, different NPI on the claim), the PA may not transfer. This is a frustrating quirk of how PBMs validate PAs at adjudication.

Building the Appeal: Structure Matters More Than Length

A good PA appeal isn't long — it's specific. PBM reviewers work through a steady queue of appeals, and a five-page letter stuffed with medical jargon isn't going to help your patient any faster than a tight, well-documented two-pager.

Your appeal should include:

1. The rejection details — date of service, drug, strength, quantity, reject code (75), and the plan ID/BIN/PCN
2. A clear statement of why the denial was incorrect or should be overturned — don't just say "we disagree," explain why
3. Clinical documentation — diagnosis codes, relevant labs, treatment history, prescriber notes supporting medical necessity
4. Evidence that step therapy or formulary alternatives have been tried (or are contraindicated) — this is critical and often missing
5. The prescriber's signature — some PBMs won't even log the appeal without it

For example, a specialty pharmacy might keep getting 75 rejects on a biosimilar for a rheumatoid arthritis patient even though the clinical documentation is solid, because its appeals never note that the patient failed two preferred agents. A clear failure-of-alternatives summary, with dates and clinical outcomes, is what closes that gap.

The level of specificity matters. "Patient requires this medication" loses every time. "Patient initiated methotrexate on 03/14/2025, discontinued 07/22/2025 due to hepatotoxicity (ALT 3x ULN, documented in attached lab results)" wins.

Timelines, Escalations, and When to Push Harder

Decision deadlines depend on the plan type. A Medicare Part D plan must decide a standard coverage determination within 72 hours and an expedited one within 24 hours (CMS); for an exception request, the 72-hour clock starts when the plan receives the prescriber's supporting statement (42 CFR 423.568). A Part D plan must decide a standard redetermination within 7 calendar days and an expedited one within 72 hours (CMS). For an employer group health plan covered by ERISA, a pre-service appeal is decided within 30 days (15 days per level if the plan has two levels) and an urgent one within 72 hours (29 CFR 2560.503-1). State law and the plan documents can set other windows. If a patient's health could deteriorate without the medication, request expedited review explicitly and document the clinical urgency in writing.

If the plan denies the PA request, don't stop there. The appeal levels depend on the plan type:

• Medicare Part D: a redetermination by the plan, requested within 65 days of the coverage determination notice (CMS), then reconsideration by the Independent Review Entity, then an ALJ hearing, the Medicare Appeals Council and federal court
• Commercial plans: an internal appeal, which members of ACA-compliant and ERISA group plans (or an authorized representative, often the prescriber) have at least 180 days from the adverse benefit determination to file; some plans add a second internal level
• External review by an Independent Review Organization (IRO): available on ACA-compliant commercial plans after a final internal denial; under the federal process it must be requested within 4 months, and state processes vary

An external review decision binds that claim only; it does not set precedent for the next patient. Don't assume a second denial means it's over.

Also: track everything. Create a simple log with the appeal date, submission method (fax, portal, phone), confirmation number, and expected response deadline. A plan that misses its deadline does not usually owe you an automatic approval. A Medicare Part D plan that misses a coverage determination or redetermination deadline must forward the case to the Independent Review Entity within 24 hours (42 CFR 423.568, 42 CFR 423.590), and a non-grandfathered commercial plan that does not strictly follow the federal claims and appeals rules can leave the member deemed to have exhausted internal appeals and free to request external review (45 CFR 147.136). Either way, you need proof of when you submitted.

Tools That Can Speed This Up

Let's be practical here. If you're managing multiple 75 rejects a week, doing this manually is exhausting and error-prone. A lot of practices and pharmacies are now using AI-powered appeal generators that pull in claim data and clinical notes to draft appeals automatically, which cuts drafting time. These tools won't replace clinical judgment, but they're genuinely useful for getting a solid first draft you can review and customize.

The key is still the clinical specificity. No tool automates that piece for you — the prescriber and clinical staff need to provide the supporting detail.

Wrapping Up: Don't Let Reject 75 Be a Dead End

A prior-authorization reject isn't a wall. Reject 75s get resolved when the PA request, and any appeal after it, is specific, well documented and backed by the right clinical detail. The practices and pharmacies that clear these steadily aren't doing anything magic. They've built a repeatable process: verify what is on file, submit the right PA request, document failed alternatives clearly, request expedited review when it's warranted, and escalate to independent review when needed.

Your next steps:

• Audit your active PAs this week — flag any expiring in the next 90 days
• Build a PA rejection log if you don't have one
• Create a standard appeal template that includes failure-of-alternatives language
• Know your PBM-specific appeal portal URLs and deadlines before the next reject hits

Your patients are counting on someone in the system to push back when the answer is wrong. Reject 75 is worth fighting, and it is often winnable.